Effects Of Treatment Of Several Medicine Union On Airway Inflammation Of Stable COPD

Objective To study the effects of the use of Salmeterol/fluticasone, N-acetylcysteine,Theophylline Sustained-release Tablet on stable COPD patients' airway inflammation,pulmonary function,and QOL(quality of life).Methods The research enrolled 132 patients with stable COPD. These patients were randomized into three groups:Group A(43)in which patients were given Salmeterol/fluticasone twice per day;Group B (42)in which patients took Salmeterol/fluticasone twice per day and N-acetylcysteine 0.6g three times per day;Group C(47)in which patients were given Salmeterol/fluticasone twice per day, N-acetylcysteine 0.6g three times per day and Theophylline Sustained-release Tablet 0.2g twice per day.The course of treatment is four weeks.All the patients were measured in pulmonary function,IL-8, TNF-α,SOD and MDA in blood serum and induced sputum.They were also examined to check cellular count and classification of induced sputum smear,and evaluated in QOL.Results After treatment FEV₁,FEV₁%,QOL evaluation,IL-8, TNF-α,total cellular count and Neu%in induced sputum have obvious contrast in group A(p＜0.05,p＜0.01);After treatment FEV₁,FEV₁%,QOL evaluation,SOD and MDA in blood serum,IL-8,TNF-α,SOD and MDA,total cellular count,Neu%and Am%in induced sputum have obvious contrast in group B(p＜0.05,p＜0.01);compared with group A, SOD and MDA in blood serum and the Neu%in induced sputum smear have significant difference.After treatment FEV₁,FEV₁%,QOL evaluation, SOD and MDA in blood serum,IL-8,TNF-α,SOD and MDA,total cellular count,Neu%and Am%in induced sputum have obvious contrast in group C(p＜0.05,p＜0.01);compared with group A,FEV₁%,QOL evaluation,SOD and MDA in blood serum and Neu%and Am%in induced sputum smear have significant difference(p＜0.05).Conclusion There are more benefits in treatment of combination of Salmeterol/fluticasone,N-acetylcysteine and Theophylline Sustained-release Tablet in pulmonary function,airway inflammation and QOL of stable COPD.